Event Panel Schedule


TBA
Gary Nach­man from BMO to dis­cuss Sol-Gel
Webcast
50aac7ca8d970a060fd5c6fdeb899b28_7fe6a3419d7d19a6d0e816c4ad7a66f7_120_120
Sol-Gel Technologies Ltd.
Alon Seri-Levy, PhD , CEO / Sol-Gel Technologies Ltd.
Dr. Alon Seri-Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design…

8c78177f94bb26cbf80e74f83c0c811f_256859639d1d75e131719f0bdc7cc792_120_120
Sol-Gel Technologies Ltd.
Gilad Mamlok , CFO / Sol-Gel Technologies Ltd.
Mr. Gilad Mamlok has served as Sol-Gel's chief financial officer since February 2017. From August 2015 to January 2017, Mr. Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv…

10b768ed45c279c3e18de475b1c0ea33_fe650289b4283ad3a7d980a3c62c5bfd_120_120
Sol-Gel Technologies Ltd.
John Vieira , US Head of Commercialization / Sol-Gel Technologies Ltd.
Mr. John Vieira has served as our U.S. head of commercialization since January 2019. Prior to joining Sol-Gel, Mr. Vieira served in U.S. and Global Marketing roles at Leo Pharmaceuticals. Prior to Leo Pharmaceuticals, Mr. Vieira was Executive…

E4e4d1e2ec69fc571f0841eca8f97eba_ad2a9363276539e99723ceb2200adbe8_120_120
BMO Capital Markets
Gary Nachman , Managing Director, Specialty Pharmaceuticals Research Analyst / BMO Capital Markets
Gary is a senior research analyst in BMO Capital Markets Equity Research covering specialty pharmaceuticals. Prior to joining BMO in February 2016, Gary was most recently a senior research analyst at Goldman Sachs covering specialty pharma. With a…

TBA
Joseph Pant­gi­nis from H.C. Wain­wright to dis­cuss Lin­eage
Webcast
F53a552f8d77ebf75992586ed85733da_caaf76bb5fb98d2554aa7128d1735370_120_120
Lineage Cell Therapeutics
Brian Culley , CEO / Lineage Cell Therapeutics
Mr. Culley joined BioTime as CEO in September 2018. Prior to joining BioTime, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management…

A446abcd0261ac027be35dc262a42016_1b79b55bdbb98548fc71db74bc480bf2_120_120
Lineage Cell Therapeutics
Brandi Roberts , CFO / Lineage Cell Therapeutics
Developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and…

C703813dbd552a3a01225f9290e7cafe_bedad4cc1de0599673b7f0eed2b2bd1a_120_120
H.C. Wainwright & Co., LLC
Joseph Pantginis, Ph.D. , Director of Research, Managing Director / H.C. Wainwright & Co., LLC
Dr. Pantginis has over 20 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he…

TBA
Sou­mit Roy from Jones Trad­ing to dis­cuss Ber­Gen­Bio
Webcast
C2170edb0a428fa3e5e3e3600c30dd13_09885c6423d80ff91d72c7b7a0f6bb86_120_120
BerGenBio
Richard Godfrey , CEO / BerGenBio
Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years’ industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of…

2e451b0432cbd236dbdebed3cf7c1382_c653092c8f8f8d36575de2d3795795b0_120_120
Jones Trading
Soumit Roy, PhD , Equity Research Analyst / Jones Trading
Soumit Roy is a Healthcare Equity Research analyst with focus on disruptive technology, primarily oncology companies developing T cell therapy, targeted medicines and next generation of immuno-oncology. Prior to joining JonesTrading in 2018, Dr. Roy…

TBA
Biren Amin from Jef­feries to dis­cuss Zen­talis
Webcast
C336e2bc01bd0c0be608b2138eda0dc7_d480ebeb810ab65c4dfa0f1cccfa739b_120_120
Zentalis
Anthony Sun , CEO / Zentalis
Anthony has played an active role across the life science industry since 2002 and currently serves as Chief Executive Officer for Zentalis Pharmaceuticals. From 2002 until 2015, he was at Aisling Capital and Perseus-Soros Biopharmaceutical Fund…

7b96017db698b7832f9e2958eb064346_267365a651dcb92baf560349fe5b0455_120_120
Zentalis
Melissa Epperly , CFO / Zentalis
Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy…

A508b1cfa3ad0a216487e60819dff8e8_189dedd9ee1fad2fae75b976e6dab314_120_120
Jefferies LLC
Biren Amin / Jefferies LLC
Amin is a senior research analyst at Jefferies, LLC. He is assisted by Hugo Ong and joined the firm in June 2011. Previously, Amin was an analyst at WJB Capital Group (February 2010-June 2011). Prior to that, he was into biotech equity research at…

TBA
Yatin Sune­ja to dis­cuss Ex­i­cure
Webcast
5d020b7eaad05468a62b038ba636f893_03d2c5587b8fa66054fabd215cec2085_120_120
Exicure
David Giljohann , CEO / Exicure
Dr. Giljohann has served as our CEO since November 2013 and been on our board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was our Chief Operating Officer. From 2011 until June 2012, Dr. Giljohann served as our…

68c2385195b85e6a81bd0e6759092b17_061874d2d0dec1c23673fab44a85b3b4_120_120
Exicure
David Snyder , CFO / Exicure
Mr. Snyder joined our executive leadership team as Chief Financial Officer in July 2014. Prior to joining the Company, Mr. Snyder was Executive Vice President and Chief Financial Officer of Cellular Dynamics International, Inc. where he was…

8450ab20ceb17b3470e1082bd36c319f_23909e70118a3dacc9eb535873db6bb5_120_120
Guggenheim Securities, LLC
Yatin Suneja , Senior Biotechnology Analyst / Guggenheim Securities, LLC
Now at Guggenheim, Yatin Suneja served at STRH as a director providing Biotech research coverage. Suneja was most recently at Cowen and Company, where he spent the last four years covering Biotech stocks. Prior to Cowen, he was a key member of the…
Export to Excel